Fundz Deep Dive

Everything you need to win Cn Bio Innovations — in one platform.

Who to reach, what to say, and why now on Cn Bio Innovations — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on Cn Bio Innovations — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply

Grounded in signals no one else has — tuned to their persona.

Signals no one else has

UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.

Verified contact + click-to-call

The decision-maker’s email and mobile — dial in-browser.

CN Bio Raises $21 Million USD in First Close of Series B Investment Round

PRIVATEApr 23, 2024•about 2 years ago

Amount Raised

$21 Million

Round Type

series b

Cambridge

Investors

Cn Innovations Holdings LtdBayland Capital

Description

CN Bio has raised $21 million in the first close of its Series B fundraising round. The funding was secured from several new investors, including $10 million from Bayland Capital and $5.5 million from founding shareholder, CN Innovations Holdings Ltd. The investment will be used to accelerate the Company’s expanding product portfolio and to scale the business to support commercial expansion across key global markets.

Company Information

Company

Cn Bio Innovations

Location

Cambridge, Massachusetts, United States

About

We generate human-specific efficacy and safety data with pioneering PhysioMimix™ single- and multi-organ-on-a-chip solutions. Our advantage comes from having had almost unparalleled resources to invest in the development of leading edge organ-chips thanks to more than $32 Million in grants and contracts from DARPA, NIH, EU FP7, Innovate UK and NC3Rs. These programs have led to the development of a 7-organ human body-on-a-chip model (DARPA), a liver-on-a-chip model of cancer metastasis (NIH), a full viral lifecycle organ-chip model of hepatitis B and a liver-on-a-chip model of non-alcoholic fatty liver disease and steatohepatitis (NAFLD/NASH). CN Bio is at the forefront of translating these promising technologies from leading academic laboratories into the hands of pharmaceutical researchers for the development of new medicines to treat and cure disease and to the wider academic community seeking to understand biology and disease pathology using technologies which more closely represent the human response.

Related People

Suggested for you

1 contact

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Cn Bio Innovations's next move

Learn about Strategic plan

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Watching Cn Bio Innovations? See every signal — funding, hires, M&A, contracts, sentiment.

Request a demo Choose your plan